Form 4: C4 Therapeutics CFO Kendra Adams Reports Stock Transactions

C4 Therapeutics' Chief Financial Officer, Kendra Adams, reports the acquisition and disposal of company stock and performance restricted stock units.

Summary

• On September 16, 2024, Kendra Adams, the Chief Financial Officer of C4 Therapeutics, Inc. [CCCC], reported transactions involving the company's stock.
• Adams acquired 2,250 shares of Common Stock through the vesting of Performance Restricted Stock Units (PRSUs).
• Simultaneously, 661 shares were withheld by the issuer to cover tax obligations related to the vesting of the PRSUs.
• Following these transactions, Adams directly owns 83,628 shares of C4 Therapeutics Common Stock and 14,250 Performance Restricted Stock Units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions without indicating a strong positive or negative outlook.

Positives

• The vesting of performance restricted stock units suggests that certain performance milestones have been met.

Negatives

• The withholding of shares to cover tax obligations reduces the net gain for the reporting person.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment about the company's prospects.

Stakeholder Impact

• Shareholders may use this information to assess management's alignment with their interests.
• Employees holding similar equity-based compensation may be interested in the vesting terms and tax implications.

Key Dates